• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, June 15

Aurobindo Pharma Ltd has announced that it has received approval from the US Food and Drug Administration (USFDA) for Trandolapril tablets of strength 1 mg, 2 mg & 4 mg. Trandolapril is the generic equivalent of Abbott's Mavik tablets, indicated for the treatment of hypertension. This is the company's fourth anti hypertensive (medicines regulating blood pressure) getting the USFDA's nod.

According to a company release, Trandolapril is an ACE inhibitor, and amongst the class, has a longer half-life. Hence it is dosed once a day. Trandolapril is also employed in combination with diuretics or other calcium channel blockers due to its beneficial synergy. The drug is a better choice in diabetic hypertensives as it helps in slowing down the onset of nephropathy besides regulating blood pressure. Trandolopril tablets enjoy a market share of around $50 million currently in the US alone.

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Aurobindo gets USFDA nod

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line